Skip Navigation


European Heart Journal Advance Access originally published online on October 30, 2008
European Heart Journal 2008 29(23):2833-2834; doi:10.1093/eurheartj/ehn494
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
29/23/2833    most recent
ehn494v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Serebruany, V. L.
Right arrow Articles by Goto, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Serebruany, V. L.
Right arrow Articles by Goto, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

The challenge of monitoring platelet response after clopidogrel

Victor L. Serebruany1,* and Shinya Goto2

1 HeartDrugTM Research Laboratories, Johns Hopkins University, Towson, MD 21204, USA
2 Department of Medicine (Cardiology), Tokai University, Kanagawa, Japan

* Corresponding author. Tel: +1 410 203 1665, Fax: +1 410 601 9061, Email: heartdrug@aol.com

This editorial refers to: ‘Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients’{dagger} by M. Lordkipanidzé et al., on page 2877

Footnotes

The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.

The first 10% of the full text of this article appears below.

Despite the established importance of platelet inhibition for the treatment or prevention of thrombotic vascular events, recent oral antiplatelet drug development cannot be considered as a uniform, complete success. In fact, the MATCH,1 CHARISMA,2 and TRITON3 trials raise concerns with regard to the vascular efficacy (questionable, if any) and the obvious increased bleeding risks that arise from more potent antiplatelet regimens. Therefore, attempts to identify the high-risk cohorts that experience worse clinical outcomes or . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients
Marie Lordkipanidzé, Chantal Pharand, Thuy Anh Nguyen, Erick Schampaert, Donald A. Palisaitis, and Jean G. Diodati
EHJ 2008 29: 2877-2885. [Abstract] [Full Text]